Teknova: The Old Story Is a Cash Burn That's Already Shrinking

The market still prices Teknova as a lab reagent company that burns cash and won't stop. The Q2 numbers say that narrative is already stale.

Revenue crossed $12 million for the first time in the company's 30-year history — $12.2 million, up 18% from a year earlier. Gross margin expanded to 40.1%. And the one metric that matters most for a business this size shrank dramatically: free cash flow outflow fell from $3.6 million in Q1 to $0.6 million in Q2. The lowest quarterly burn since the IPO.

That's the inflection the market hasn't fully digested.

The old story

Teknova manufactures custom and catalog reagents for biotech, pharma, and academic labs. It has been growing steadily — low-double-digit revenue growth for two years — but the growth was always offset by operating losses. The company spent more on R&D, sales, and infrastructure than it generated in profit. The market treated TKNO as a company that might eventually show discipline but had never really shown it.

That story made sense when every quarter looked the same: revenue growing, losses continuing, cash depleting.

What changed

Q2 broke that pattern on the cash-flow side even if it didn't on the headline P&L. The net loss was still there — $3.2 million, or -$0.06 per diluted share — but the cash outflow is a different number from accounting losses, and it's the one that determines whether the balance sheet can hold.

Free cash flow outflow of $0.6 million in Q2, compared to $3.6 million just three months prior and $2.3 million a year ago. The compression came from operating cash use dropping to $0.5 million (from $2.1 million year-over-year) and disciplined capital spending of just $0.1 million. Working capital management improved — inventory draws used $0.4 million versus $1.5 million in Q2 2025.

Gross profit grew 64% to $4.9 million. That margin expansion to 40.1% came from higher volume absorbing fixed manufacturing costs — the same operating leverage that management said would drive the business toward breakeven.

Both segments hit the same growth rate: Lab Essentials ($9.2 million, up 18%) and Clinical Solutions ($2.4 million, up 18%). Growth was broad-based across target markets, with only cell and gene therapy — roughly 24% of revenue — showing weakness. The largest direct customer still represents less than 7% of quarterly revenue.

The math behind the margin improvement tells you why the cash burn is collapsing. Management stated that incremental revenue drops through at approximately 70% contribution margin because of fixed cost absorption. That means each additional dollar of revenue flows almost entirely toward covering operating expenses. On a revenue base accelerating toward $46 million, that leverage starts to close the gap fast.

The proof path to EBITDA breakeven

Management didn't use the word "profitable" on the earnings call, but they laid out a specific bridge. Adjusted EBITDA breakeven — earnings before interest, taxes, depreciation, and amortization, stripped of stock-based compensation — requires an annualized revenue run rate of $52 million to $57 million. They see that happening by the end of 2027.

Here's why that target is more credible than most turnaround bridges I've seen: the assumptions are stated in plain numbers, not vibes. Low double-digit revenue growth. 70% contribution margin on incremental revenue. Operating expense growth held in check. Roughly $2 million in annual capex.

Q2 2026 delivered the fastest revenue quarter on record. Full-year guidance was raised to $45-$47 million, up from the prior $42-$44 million range. If the company hits the midpoint of $46 million and the Q2 run rate of $12.2 million holds or improves, the annualized number sits at $48.8 million — within striking distance of the breakeven zone. Management sees about 20% growth in 2027, putting revenue in the $55 million range. That lands squarely in the profitability window.

The balance sheet is the risk

This is where the thesis gets real. Teknova holds $17.4 million in cash and short-term investments against $13.2 million in total borrowings — a net cash position of roughly $4 million. That's thin.

First-half free cash outflow was $4.2 million. Management guided full-year outflow to less than $8 million. If they hit $7.5 million, that leaves $3.3 million of burn in H2 and ending cash of roughly $9.9 million. That gets them through mid-2027 without raising capital — assuming the trajectory holds. Management explicitly said they expect to reach the profitability inflection with the existing capital base.

But there's no fat. A return to Q1's $3.6 million quarterly burn would rapidly corner the balance sheet. A revenue miss that pushes full-year below the $45 million floor extends the runway problem. The cell and gene therapy slowdown, which accounts for nearly a quarter of revenue, is the single largest operational headwind.

Why the market hasn't priced this in yet

TKNO is up 223% over the past 120 days and 70% year-to-date, trading around $6.46 with a market cap of $347 million. The stock has run hard on this quarter. But the valuation still reflects a company that loses money on every dollar it earns — 7.8 times trailing sales, negative operating margins, and a TTM free cash flow margin of -16.8%. That multiple would be absurd for a profitable growth company. For a pre-profitability operator, it's not cheap, but it's not requiring infinite patience either.

The stock is still priced as a company that needs to prove it can stop burning cash. The Q2 number says it already has. The gap between those two views is the setup.

When conviction is high, you attach numbers

If Teknova reaches $55 million in annual revenue by 2027 and achieves EBITDA breakeven as management projects, the market has to stop pricing it as a cash-burn play. A 5x forward revenue multiple on $55 million implies a $275 million market cap — roughly $5.30 per share. That sounds like downside from $6.46, but it assumes zero multiple expansion and no recognition of the inflection. A 6x forward multiple — not generous for a profitable specialty life sciences company — implies $330 million, or roughly $6.30.

The near-term valuation bridge is modest. But the 2027 bridge where the company becomes EBITDA-positive while still growing revenue in the low-20% range is worth more than the current market cap if the execution holds. Simple forward multiples on a turning business beat complex DCF models, especially when the DCF inputs are negative cash flows.

This isn't about excitement. It's about a business that may soon look much harder to dismiss once the free cash flow turns positive.

The setup, the risk, the tripwire

What must happen: Revenue stays at or above the $11 million quarterly pace. Free cash outflow remains at or below $1 million per quarter through 2027. No dilutive capital raise before EBITDA breakeven.

The target: If 2027 hits the $52-57 million revenue run rate and the company reaches adjusted EBITDA profitability as guided, a 6x forward revenue multiple implies roughly $7-$8 per share. Timeframe: 12-18 months.

The tripwire: A quarter where revenue falls below $10 million or free cash outflow returns above $3 million, or any indication of a dilutive capital raise before the profitability inflection. If that happens, the bridge to breakeven is broken, the runway shrinks, and the thesis invalidates. Discipline over ego.

I can be wrong again. But the setup is specific: expectations are already at the low point, the cash burn is collapsing, revenue is accelerating, and the mathematical path to EBITDA breakeven is explicit. That's the inflection before consensus feels comfortable.